Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by pabalooon Mar 27, 2020 4:12am
79 Views
Post# 30851949

RE:Cipher Pharma has price target cut at Stifel Canada

RE:Cipher Pharma has price target cut at Stifel CanadaNot sure if he cut our revenues to 20 million due to covid or he thinks the business is waning. He also chopped earnings to 5 million which is so low after a spectacular last quarter not adding even a penny for future products.  Sounds to me he's not looking at the same company I'm seeing unless it's falling off a cliff. I'm guessing next quarter we should be good for 5 million alone in revenue as covid didn't really affect the market until mid March. Q2 could be a write off if 
this prolongs but I still see Q3and Q4 as strong as Q1. Also remember we have almost no staff that are being paid during this pandemic so they can ride out this wave for a few months.Hoping for a green day tomorrow.
Bullboard Posts